The new serial entrepreneur in the biotech arena launches another upstart looking to drug RNA
After a lifetime of entrepreneurship, Bill Haney has discovered how much fun it can be to set up new biotechs.
A year after launching the cancer startup Dragonfly — allying himself with MIT’s Tyler Jacks and David Raulet out of Berkeley — he’s now back with his second upstart called Skyhawk Therapeutics, which is jumping into the fast-growing new company segment focused on drugging RNA with small molecules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
